This non-interventional, observational study investigates the efficacy, safety and usability of methoxy polyethylene glycol epoetin beta in participants on peritoneal dialysis. Participants who were prescribed methoxy polyethylene glycol epoetin beta by their doctor and who meet the selection criteria were to be enrolled and documented in this study for a period of 9 months of treatment with methoxy polyethylene glycol epoetin beta with respect to efficacy, safety and usability.
Study Type
OBSERVATIONAL
Enrollment
223
Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
Dres. Michael Koch Hannelore Klimke Wolfgang Kulas u.w.
Mettmann, Germany
Percentage of Participants With Hemoglobin Values in the Range of 11-12 Grams Per Deciliter (g/dL) During the Evaluation Period of Visit 7 (Month 7) to Visit 9 (Month 9)
Time frame: Month 7 to Month 9
Percentage of Participants With Hemoglobin Values in the Range of 11-13 g/dL During the Evaluation Period of Visit 7 (Month 7) to Visit 9 (Month 9)
Time frame: Month 7 to Month 9
Average Duration in Days Mircera Was Administered at a Stable Dose
Time frame: Up to 9 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.